Xu Chong, He Jinhan, Jiang Hongfeng, Zu Luxia, Zhai Wenjie, Pu Shenshen, Xu Guoheng
Department of Physiology and Pathophysiology, Peking University Health Science Center, the Ministry of Education of China, Beijing 100191, China.
Mol Endocrinol. 2009 Aug;23(8):1161-70. doi: 10.1210/me.2008-0464. Epub 2009 May 14.
Hypercortisolemia and glucocorticoid treatment cause elevated level of circulating free fatty acids (FFAs). The basis of this phenomenon has long been linked to the effect of glucocorticoids permitting and enhancing the adipose lipolysis response to various hormones. In this study, we demonstrate that glucocorticoids directly stimulate lipolysis in rat primary adipocytes in a dose- and time-responsive manner; this lipolytic action was attenuated by treatment with the glucocorticoid antagonist RU486. Dexamethasone down-regulates mRNA and protein levels of cyclic-nucleotide phosphodiesterase 3B, thereby elevating cellular cAMP production and activating protein kinase A (PKA). On inhibition of PKA but not other kinases, the lipolysis response ceases. Furthermore, dexamethasone induces phosphorylation and down-regulation of perilipin, a lipid droplet-associating protein that modulates lipolysis; this effect is restored by RU486 or PKA inhibitor H89. Dexamethasone up-regulates mRNA and protein levels of hormone-sensitive lipase (HSL) and adipose triglyceride lipase; these effects, parallel to increased lipolysis, are attenuated by RU486 or actinomycin D. Phosphorylation at Ser-563 and Ser-660 residues of HSL and activity of cellular lipases are elevated on dexamethasone stimulation but abrogated by the coaddition of H89. However, dexamethasone does not induce HSL translocation to the lipid droplet surface in differentiated adipocytes. We show that elevated FFA concentration in plasma is associated with increased lipase activity and lipolysis in vivo in adipose tissues of dexamethasone-treated rats. Therefore, the lipolytic action of glucocorticoids liberates FFA efflux from adipocytes to the bloodstream, which could be a cellular basis of systemic FFA elevation in response to glucocorticoid challenge.
高皮质醇血症和糖皮质激素治疗会导致循环游离脂肪酸(FFA)水平升高。长期以来,这种现象的基础一直与糖皮质激素允许并增强脂肪组织对各种激素的脂解反应的作用有关。在本研究中,我们证明糖皮质激素以剂量和时间依赖性方式直接刺激大鼠原代脂肪细胞的脂解作用;这种脂解作用可被糖皮质激素拮抗剂RU486处理所减弱。地塞米松下调环核苷酸磷酸二酯酶3B的mRNA和蛋白水平,从而提高细胞内cAMP的产生并激活蛋白激酶A(PKA)。抑制PKA而非其他激酶时,脂解反应停止。此外,地塞米松诱导 perilipin(一种调节脂解的脂滴相关蛋白)的磷酸化和下调;这种作用可被RU486或PKA抑制剂H89恢复。地塞米松上调激素敏感性脂肪酶(HSL)和脂肪甘油三酯脂肪酶的mRNA和蛋白水平;这些作用与脂解增加平行,可被RU486或放线菌素D减弱。地塞米松刺激后,HSL的Ser-563和Ser-660残基的磷酸化以及细胞脂肪酶的活性升高,但同时加入H89可消除这种升高。然而,地塞米松不会诱导分化的脂肪细胞中HSL转位至脂滴表面。我们发现,地塞米松处理的大鼠血浆中FFA浓度升高与脂肪组织中体内脂肪酶活性增加和脂解增加有关。因此,糖皮质激素的脂解作用使FFA从脂肪细胞释放到血液中,这可能是糖皮质激素刺激后全身FFA升高的细胞基础。